Prostate Tumor Marker Antibody (YPMA-2): sc-52882
- Prostate Tumor Marker Antibody (YPMA-2) is a mouse monoclonal IgG3 κ Prostate Tumor Marker antibody provided at 100 µg/ml
- raised against PMA of human origin
- recommended for detection of Prostate mucin antigen of human origin by WB and IF; non cross-reactive with fetal or benign prostate specimens, non-prostate carcinomas and normal human tissues
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Prostate Tumor Marker Antibody (YPMA-2). This work is in progress.
QUICK LINKS
SEE ALSO...
Prostate Tumor Marker Antibody (YPMA-2) is a mouse monoclonal IgG3 kappa light chain antibody that detects the Prostate Tumor Marker protein of human origin by western blotting (WB) and immunofluorescence (IF). Anti-Prostate Tumor Marker antibody (YPMA-2) is available as the non-conjugated form. Prostate cancer, the most prevalent non-skin cancer affecting men in the United States, arises from mutations in prostate cells that lead to uncontrolled proliferation. These malignant cells can spread to various parts of the body, including the bones, lymph nodes, rectum, and bladder, making early detection crucial for effective treatment. Prostate Tumor Marker (YPMA-2) antibody plays a significant role in this context, as Prostate Tumor Marker protein is associated with the unique molecular profile of prostate tumors, which can serve as valuable biomarkers for diagnosis and therapeutic monitoring. Notably, Prostate Tumor Marker protein undergoes specific post-translational modifications, such as glycosylation, which can influence stability, localization, and interaction with other proteins. These modifications are essential for Prostate Tumor Marker protein′s function and can affect the tumor′s behavior, making them critical for understanding the disease′s progression and response to treatment. The identification of these modifications can also aid in the development of targeted therapies, enhancing the precision of prostate cancer management.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Prostate Tumor Marker Antibody (YPMA-2) References:
- Amperometric biosensors for detection of the prostate cancer marker (PSA). | Sarkar, P., et al. 2002. Int J Pharm. 238: 1-9. PMID: 11996805
- Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. | Miller, DC., et al. 2003. Cancer. 98: 1169-78. PMID: 12973840
- Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). | Roobol, MJ., et al. 2004. Urology. 63: 309-13; discussion 313-5. PMID: 14972478
- Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. | Jerónimo, C., et al. 2004. Clin Cancer Res. 10: 4010-4. PMID: 15217932
- Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. | Jiang, Z., et al. 2004. Histopathology. 45: 218-25. PMID: 15330799
- [Pro PSA: a new prostate cancer marker]. | Peyromaure, M. 2004. Prog Urol. 14: 8-11. PMID: 15776578
- Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. | van der Cruijsen-Koeter, IW., et al. 2005. J Urol. 174: 121-5. PMID: 15947595
- The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. | Struewing, JP., et al. 1997. N Engl J Med. 336: 1401-8. PMID: 9145676
- Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. | Darson, MF., et al. 1997. Urology. 49: 857-62. PMID: 9187691
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Prostate Tumor Marker Antibody (YPMA-2) | sc-52882 | 100 µg/ml | $322.00 |